MRNA

SEC source: 0001127602-20-032413 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,734,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020.

SEC source: 0001127602-20-032394 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,523,868

F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020.

F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person.

SEC source: 0001127602-20-032394 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,524,868

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.

SEC source: 0001127602-20-032211 · form4.xml · derivative · entry 14

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,790 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F11 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001127602-20-032211 · form4.xml · derivative · entry 13

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,952

Underlying: Common Stock · 2,339 shares

Expires 2027-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F10 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

SEC source: 0001127602-20-032211 · form4.xml · derivative · entry 12

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,998

Underlying: Common Stock · 10,000 shares

Expires 2029-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 11

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.10 to $146.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 10

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.77 to $145.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 9

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,882

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.71 to $144.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 8

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,182

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.70 to $143.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 7

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,597

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.57 to $142.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,617

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.41 to $141.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,493

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.40 to $140.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,528

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.93 to $138.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,129

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,339

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-032211 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 10

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,050,372

F11 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.

F12 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 9

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 254,074

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 8

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 254,174

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.45 to $143.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 7

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 254,774

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.30 to $143.06. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 6

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 255,974

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.00 to $141.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 5

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 256,788

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.99 to $140.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 4

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 258,947

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $138.80 to $139.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 260,633

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.73 to $138.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 262,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.68 to $137.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-032204 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 264,620

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $135.62 to $136.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-031970 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,624,880

F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020.

F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-031970 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,533,868

F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020.

F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person.

SEC source: 0001127602-20-031970 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,534,868

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.

SEC source: 0001127602-20-031540 · form4.xml · derivative · entry 5

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 687,431

Underlying: Common Stock · 10,000 shares

Expires 2023-08-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020.

F3 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001127602-20-031540 · form4.xml · nonDerivative · entry 2

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,724,597

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020.

SEC source: 0001127602-20-031540 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,744,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020.

SEC source: 0001127602-20-031532 · form4.xml · derivative · entry 17

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,790

Underlying: Common Stock · 10,000 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F13 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001127602-20-031532 · form4.xml · derivative · entry 16

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,291

Underlying: Common Stock · 5,000 shares

Expires 2027-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F12 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

SEC source: 0001127602-20-031532 · form4.xml · derivative · entry 15

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,175

Underlying: Common Stock · 34 shares

Expires 2028-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F11 · derivative.exercise_date: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-20-031532 · form4.xml · derivative · entry 14

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,998

Underlying: Common Stock · 10,000 shares

Expires 2029-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 13

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.48 to $162.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 12

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 701

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.34 to $162.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 11

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,203

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.17 to $161.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 10

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,110

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.14 to $160.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 9

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,468

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.10 to $158.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 8

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,468

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.77 to $157.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 7

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,977

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.73 to $156.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,899

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.68 to $155.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,632

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.67 to $154.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

SEC source: 0001127602-20-031532 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.